Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Summary
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development
Description
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source